In vitro antimicrobial effect and in vivo preventive and therapeutic effects of partially purified lantibiotic lacticin NK34 against infection by Staphylococcus species isolated from bovine mastitis.
Lantibiotics are small (<5 kDa), polycyclic peptides produced by gram-positive bacteria; they are also known as gram-positive bacteriocins. The high antimicrobial activity of lacticins and the continuing appearance of antibiotic-resistant bacteria in recent years have resulted in a renewed interest in lantibiotics. A partially purified form of lacticin NK34 (a Lactococcus lactis product isolated from the Korean fermented fish jeotgal) was tested to determine its antimicrobial effects against Staphylococcus aureus (n=20) and coagulase-negative Staphylococcus (CNS, n=20) strains isolated from the raw milk of cows with subclinical bovine mastitis in the present study. The spot-on-lawn assay was used to identify the 2 strains from each group with the greatest lacticin NK34 susceptibility, and the minimal lethal dose (MLD) was measured in ICR (imprinting control region) mice. The preventive and therapeutic effects of lacticin NK34 on the mouse infection model were determined for the first time. Lacticin NK34 demonstrated antimicrobial effects in 14 of 20 (70%) S. aureus indicator strains and in 18 of 20 (90%) CNS strains. Staphylococcus aureus 69 and S. simulans 55 demonstrated the greatest susceptibility to lacticin NK34 in the spot-on-lawn assay. The S. aureus 69 MLD was measured at 1.53 x 10(9) cfu/mouse, whereas the S. simulans 55 MLD was 3.59 x 10(9) cfu/mouse. Mice infected experimentally with S. aureus 69 MLD or S. simulans 55 MLD were treated with lacticin NK34. Treated mice demonstrated an 80% survival rate (48 of 60 mice) compared with a survival rate of 7.5% (3 of 40 mice) in control mice treated with distilled water. These data suggest that lacticin NK34 might be useful in the control of bovine mastitis and systemic bacterial infection.
Kim
S Y
SY
Department of Microbiology, College of Veterinary Medicine and BK21 Program for Veterinary Science, Seoul National University, Seoul 151-742, Korea.
Shin
S
S
Koo
H C
HC
Youn
J-H
JH
Paik
H-D
HD
Park
Y H
YH
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001430:Bacteriocins / Q000627:therapeutic use*; D002417:Cattle; D046508:Culture Techniques; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000662:veterinary; D005260:Female; D013294:Lactococcus lactis / Q000378:metabolism; D008414:Mastitis, Bovine / Q000382:microbiology / Q000517:prevention & control*; D051379:Mice; D008892:Milk / Q000382:microbiology; D013203:Staphylococcal Infections / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D013210:Staphylococcus / Q000187:drug effects* / Q000302:isolation & purification; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D001430:Bacteriocins; C553311:lacticin NK34, Lactococcus lactis